CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 118 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $384,000 | -4.0% | 88,102 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $400,000 | -20.9% | 88,102 | 0.0% | 0.01% | -22.2% |
| Q4 2020 | $506,000 | -20.7% | 88,102 | 0.0% | 0.02% | -25.0% |
| Q3 2020 | $638,000 | +107.8% | 88,102 | 0.0% | 0.02% | +100.0% |
| Q2 2020 | $307,000 | +136.2% | 88,102 | 0.0% | 0.01% | +100.0% |
| Q1 2020 | $130,000 | -24.9% | 88,102 | 0.0% | 0.01% | -14.3% |
| Q4 2019 | $173,000 | -61.6% | 88,102 | 0.0% | 0.01% | -65.0% |
| Q3 2019 | $451,000 | -28.5% | 88,102 | 0.0% | 0.02% | -23.1% |
| Q2 2019 | $631,000 | -66.5% | 88,102 | -48.2% | 0.03% | -61.8% |
| Q3 2018 | $1,883,000 | -17.4% | 169,962 | 0.0% | 0.07% | -21.8% |
| Q2 2018 | $2,281,000 | +3.3% | 169,962 | 0.0% | 0.09% | +1.2% |
| Q1 2018 | $2,208,000 | +14.3% | 169,962 | -19.1% | 0.09% | +14.7% |
| Q4 2017 | $1,932,000 | +14.2% | 209,962 | 0.0% | 0.08% | +25.0% |
| Q3 2017 | $1,692,000 | – | 209,962 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |